TABLE 3.
Patients Who Failed Effectiveness Criteria with Second-Line TIMs for the Treatment of RAa
| Patients Who Failed Criterion, n (%) | ABA (n = 166) | ADA (n = 113) | CER (n = 42) | ETN (n = 92) | GOL (n = 36) | INF (n = 47) | TOC (n = 98) | TOF (n = 111) | All Patients (N = 705) |
|---|---|---|---|---|---|---|---|---|---|
| Any criterion | 136 (81.9) | 88 (77.9) | 36 (85.7) | 63 (68.5) | 28 (77.8) | 37 (78.7) | 68 (69.4) | 87 (78.4) | 543 (77.0) |
| Nonadherenceb | 117 (70.5) | 67 (59.3) | 34 (81.0) | 52 (56.5) | 23 (63.9) | 21 (44.7) | 49 (50.0) | 72 (64.9) | 435 (61.7) |
| Increased biologic dose | 2 (1.2) | 11 (9.7) | 1 (2.4) | 0 | 0 | 18 (38.3) | 0 | 0 | 32 (4.5) |
| Added new cDMARDc | 11 (6.6) | 10 (8.8) | 2 (4.8) | 4 (4.3) | 9 (25.0) | 4 (8.5) | 7 (7.1) | 11 (9.9) | 58 (8.2) |
| Switched biologicd | 63 (38.0) | 41 (36.3) | 15 (35.7) | 26 (28.3) | 13 (36.1) | 15 (31.9) | 36 (36.7) | 36 (32.4) | 245 (34.8) |
| Initiated/increased dose of oral glucocorticoids | 39 (23.5) | 24 (21.2) | 8 (19.0) | 13 (14.1) | 7 (19.4) | 5 (10.6) | 21 (21.4) | 32 (28.8) | 149 (21.1) |
| ≥ 2 intra-articular injections | 17 (10.2) | 13 (11.5) | 4 (9.5) | 7 (7.6) | 5 (13.9) | 6 (12.8) | 11 (11.2) | 15 (13.5) | 78 (11.1) |
aSecond-line defined as patients with experience of a biologic agent in the baseline period that is different than the index biologic agent.
bFor self-administered drugs (abatacept SC, adalimumab, certolizumab, etanercept, golimumab SC, and tocilizumab SC) and tofacitinib, nonadherence was defined as a medication possession ratio of less than 80%. For infused drugs (abatacept IV, golimumab IV, and tocilizumab IV), a proportion of days covered was calculated using the expected duration of clinical benefit. For infliximab, nonadherence was defined as not enough infusions corresponding to the lower end of the permissible dosing schedule.
cDefined as the new use of a conventional DMARD (leflunomide, methotrexate, sulfasalazine, or hydroxychloroquine), i.e., patients with no baseline conventional DMARD use or patients who initiate a new conventional DMARD.
dPatient had a claim for a biologic that was different than index biologic during the follow-up period. The biologics used to determine a switch in therapy included abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, and tofacitinib.
ABA = abatacept; ADA = adalimumab; cDMARD = conventional disease-modifying antirheumatic drug; CER = certolizumab pegol; ETN = etanercept; GOL = golimumab;
INF = infliximab; IV = intravenous; SC = subcutaneous; TIM = targeted immunomodulator; TOC = tocilizumab; TOF = tofacitinib.